secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2024-07-03T23:59:59+00:00
Accession:  0001437749-24-022188
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pieris Pharmaceuticals' Servier collaboration terminated; S095012 Phase 1 halted on safety concern
--------------------------------------------------------------------------------

- Servier terminated license/collaboration agreement effective Dec 27, 2024, citing a potential safety concern in the S095012 Phase 1 study.
- Pieris will discontinue all development of S095012; no further pursuit of the asset.
- Non-exclusive Anticalin platform license also terminates with the collaboration agreement.
- Pieris remains eligible for milestones from Boston Pharma and Pfizer partnerships on other 4-1BB bispecific assets: up to $200M development and >$415M commercial milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000143774924022188/0001437749-24-022188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000143774924022188/pirs20240612_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-022188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer